CDC panel wants more data before deciding whether to resume use of Johnson & Johnson vaccine

A Centers for Disease Control and Prevention advisory panel decided in an emergency meeting on Wednesday that members need more data before voting on how to proceed with Johnson & Johnson's one-dose COVID-19 vaccine.

On Tuesday, the CDC and Federal Drug Administration recommended a pause in using the Johnson & Johnson vaccine after six women who received it developed rare brain blood clots. One of the women died. The panel is seeking more information on the clots, including the risk factors and frequency, and will reconvene in the next seven to 10 days.

Dr. Lynn Batha, an epidemiologist at the Minnesota Department of Health and a member of the CDC advisory panel, said she supported extending the pause because "by having more robust information, I think we can be more confident about how we talk about the safety of this vaccine."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Johnson & Johnson's vaccine is one of three authorized for use in the U.S., and because only one shot is needed and doses can be stored at normal refrigerator temperatures, it is considered the best option for people who are vulnerable, like those who are incarcerated or homeless.